全文获取类型
收费全文 | 6975篇 |
免费 | 422篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 50篇 |
儿科学 | 144篇 |
妇产科学 | 123篇 |
基础医学 | 979篇 |
口腔科学 | 407篇 |
临床医学 | 637篇 |
内科学 | 1460篇 |
皮肤病学 | 104篇 |
神经病学 | 501篇 |
特种医学 | 302篇 |
外科学 | 1189篇 |
综合类 | 29篇 |
一般理论 | 3篇 |
预防医学 | 449篇 |
眼科学 | 80篇 |
药学 | 521篇 |
中国医学 | 16篇 |
肿瘤学 | 418篇 |
出版年
2023年 | 31篇 |
2022年 | 41篇 |
2021年 | 103篇 |
2020年 | 74篇 |
2019年 | 90篇 |
2018年 | 152篇 |
2017年 | 121篇 |
2016年 | 139篇 |
2015年 | 154篇 |
2014年 | 164篇 |
2013年 | 304篇 |
2012年 | 422篇 |
2011年 | 415篇 |
2010年 | 268篇 |
2009年 | 259篇 |
2008年 | 384篇 |
2007年 | 391篇 |
2006年 | 400篇 |
2005年 | 432篇 |
2004年 | 414篇 |
2003年 | 388篇 |
2002年 | 362篇 |
2001年 | 95篇 |
2000年 | 82篇 |
1999年 | 96篇 |
1998年 | 83篇 |
1997年 | 68篇 |
1996年 | 62篇 |
1995年 | 71篇 |
1994年 | 55篇 |
1993年 | 43篇 |
1992年 | 75篇 |
1991年 | 84篇 |
1990年 | 84篇 |
1989年 | 84篇 |
1988年 | 84篇 |
1987年 | 93篇 |
1986年 | 77篇 |
1985年 | 90篇 |
1984年 | 69篇 |
1983年 | 43篇 |
1982年 | 55篇 |
1981年 | 45篇 |
1980年 | 32篇 |
1979年 | 40篇 |
1978年 | 40篇 |
1977年 | 30篇 |
1976年 | 25篇 |
1974年 | 33篇 |
1973年 | 27篇 |
排序方式: 共有7412条查询结果,搜索用时 15 毫秒
171.
Ben Lu Daniel J. Antoine Kevin Kwan Peter Lundb?ck Heidi W?h?maa Hanna Schierbeck Melissa Robinson Marieke A. D. Van Zoelen Huan Yang Jianhua Li Helena Erlandsson-Harris Sangeeta S. Chavan Haichao Wang Ulf Andersson Kevin J. Tracey 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(8):3068-3073
Extracellular high-mobility group box (HMGB)1 mediates inflammation during sterile and infectious injury and contributes importantly to disease pathogenesis. The first critical step in the release of HMGB1 from activated immune cells is mobilization from the nucleus to the cytoplasm, a process dependent upon hyperacetylation within two HMGB1 nuclear localization sequence (NLS) sites. The inflammasomes mediate the release of cytoplasmic HMGB1 in activated immune cells, but the mechanism of HMGB1 translocation from nucleus to cytoplasm was previously unknown. Here, we show that pharmacological inhibition of JAK/STAT1 inhibits LPS-induced HMGB1 nuclear translocation. Conversely, activation of JAK/STAT1 by type 1 interferon (IFN) stimulation induces HMGB1 translocation from nucleus to cytoplasm. Mass spectrometric analysis unequivocally revealed that pharmacological inhibition of the JAK/STAT1 pathway or genetic deletion of STAT1 abrogated LPS- or type 1 IFN-induced HMGB1 acetylation within the NLS sites. Together, these results identify a critical role of the JAK/STAT1 pathway in mediating HMGB1 cytoplasmic accumulation for subsequent release, suggesting that the JAK/STAT1 pathway is a potential drug target for inhibiting HMGB1 release.High-mobility group box 1 (HMGB1), a ubiquitous DNA-binding protein, is a promiscuous sensor driving nucleic acid-mediated immune responses and a pathogenic inflammatory mediator in sepsis, arthritis, colitis, and other disease syndromes (1–5). Immune cells actively release HMGB1 after activation by exposure to pathogen-associated molecular patterns or damage-associated molecular patterns, including lipopolysaccharide (LPS) and inflammasome agonists (1, 6, 7). High levels of extracellular HMGB1 accumulate in patients with infectious and sterile inflammatory diseases. Extracellular disulfide HMGB1 stimulates macrophages to release TNF and other inflammatory mediators by binding and signaling through Toll-like receptor (TLR)4. Reduced HMGB1 facilitates immune cell migration by interacting with the receptor for advanced glycation end products (RAGE) and CXCL12 (8–12), a process regulated by posttranslational redox-dependent mechanisms. Administration of neutralizing anti-HMGB1 mAbs or other HMGB1 antagonists significantly reduces the severity of inflammatory disease, promotes bacterial clearance during Pseudomonas aeruginosa or Salmonella typhimurium infection and attenuates memory impairment in sepsis survivors (1, 13–15). Together, these and other findings indicate the importance of a mechanistic understanding of HMGB1 release from activated immune cells and the regulatory signaling pathways controlling these processes.Most cytokines harbor a leader peptide that facilitates secretion through the endoplasmic reticulum–Golgi exocytotic route. HMGB1, which lacks a leader peptide, is released via unconventional protein secretion pathways (1, 6, 7). In quiescent cells, most HMGB1 is localized in the nucleus. Upon activation of immune cells, efficient HMGB1 release requires acetylation of HMGB1 within the two nuclear localization sequence (NLS) sites and subsequent HMGB1 accumulation in the cytoplasm (1, 6, 16–20). HMGB1 release is mediated by inflammasome activation during pyroptosis, a form of proinflammatory programmed cell death (6, 7, 22–24). Protein kinase (PK)R is a critical regulator of inflammasome-dependent HMGB1 release (6, 25). Pharmacological inhibition of PKR abrogates LPS-induced HMGB1 release by macrophages but does not prevent nuclear translocation of HMGB1 to cytoplasm. This suggests that some other, as yet unknown, inflammasome-independent pathway regulates HMGB1 translocation from nucleus to cytoplasm.We and others have previously established an important role of type 1 and type 2 interferons (IFNs) and downstream JAK/STAT1 signaling activation in mediating HMGB1 release (26–28). Pharmacological inhibition of JAK/STAT, genetic deletion of STAT1, or inhibition of extracellular IFN-β with neutralizing antibodies significantly abrogates LPS-induced HMGB1 release from macrophages (26–28). Importantly, pharmacological inhibition of the JAK/STAT1 pathway, genetic deletion of STAT1, or inhibition of IFN-β expression by genetic deletion of IRF3 significantly promotes survival in both lethal endotoxemia and experimental sepsis (28–30). Accordingly, we reasoned here that JAK/STAT1 may represent a critical signaling mechanism controlling HMGB1 translocation from nucleus to cytoplasm. 相似文献
172.
173.
174.
PC Hallal LB Andersen FC Bull R Guthold W Haskell U Ekelund;Lancet Physical Activity Series Working Group 《Lancet》2012,380(9838):247-257
To implement effective non-communicable disease prevention programmes, policy makers need data for physical activity levels and trends. In this report, we describe physical activity levels worldwide with data for adults (15 years or older) from 122 countries and for adolescents (13-15-years-old) from 105 countries. Worldwide, 31·1% (95% CI 30·9-31·2) of adults are physically inactive, with proportions ranging from 17·0% (16·8-17·2) in southeast Asia to about 43% in the Americas and the eastern Mediterranean. Inactivity rises with age, is higher in women than in men, and is increased in high-income countries. The proportion of 13-15-year-olds doing fewer than 60 min of physical activity of moderate to vigorous intensity per day is 80·3% (80·1-80·5); boys are more active than are girls. Continued improvement in monitoring of physical activity would help to guide development of policies and programmes to increase activity levels and to reduce the burden of non-communicable diseases. 相似文献
175.
ILR Genetics Consortium Emerging Risk Factors Collaboration Sarwar N Butterworth AS Freitag DF Gregson J Willeit P Gorman DN Gao P Saleheen D Rendon A Nelson CP Braund PS Hall AS Chasman DI Tybjærg-Hansen A Chambers JC Benjamin EJ Franks PW Clarke R Wilde AA Trip MD Steri M Witteman JC Qi L van der Schoot CE de Faire U Erdmann J Stringham HM Koenig W Rader DJ Melzer D Reich D Psaty BM Kleber ME Panagiotakos DB Willeit J Wennberg P Woodward M Adamovic S Rimm EB Meade TW Gillum RF Shaffer JA 《Lancet》2012,379(9822):1205-1213
176.
Fahlke C Berggren U Berglund KJ Zetterberg H Blennow K Engel JA Balldin J 《Alcoholism, clinical and experimental research》2012,36(1):97-103
Background: Alcohol dependence has been associated with reduced function of serotonin, dopamine as well as noradrenaline activities in several neuroendocrine studies. To our knowledge, there is, however, no study investigating all these 3 systems with the use of neuroendocrine methods in one and the same alcohol‐dependent individual. Methods: Alcohol‐dependent individuals (n = 42) and controls (n = 28) participated in the neuroendocrine test series. Central serotonergic neurotransmission was assessed by the prolactin (PRL) response to citalopram (CIT). The postsynaptic DRD2 function was measured by the growth hormone (GH) response to apomorphine (APO) and the postsynaptic α2‐adrenoceptor function by GH response to clonidine (CLON). Results: In the alcohol‐dependent individuals, the PRL concentrations were significantly lower at the time points 240 minutes and 300 minutes after CIT administration and mean delta PRL value was significantly reduced by 45% in comparison with controls. There were no significant differences in APO‐GH and CLON‐GH concentrations at any time points or in mean delta GH values between the groups. An impaired monoaminergic profile, including all 3 systems, was significantly more frequent in alcohol‐dependent individuals than controls (43% vs. 6% respectively). Conclusions: The monoaminergic dysfunction was restricted to an impairment of the serotonergic system, suggesting that this system is especially vulnerable to long‐term and excessive alcohol consumption. Moreover, impaired monoaminergic profiles, including low responses in 2 or 3 systems, were more frequently observed in alcohol‐dependent individuals than in controls. Such impaired profiles may be of clinical importance, but further studies are needed. 相似文献
177.
Antonio Barone DDS PhD MSc Massimiliano Ricci DDS PhD student Ugo Covani MD DDS Ulf Nannmark DDS PhD Iman Azarmehr DDS Josè Luis Calvo‐Guirado DDS 《Clinical implant dentistry and related research》2012,14(3):373-379
Background: Insufficient alveolar bone height often prevents the placement of standard dental implants in the posterior part of edentulous maxilla. In order to increase adequately the vertical dimension of the reabsorbed alveolar process, a sinus lift procedure is often necessary. The aim of this study was to evaluate histologic results of a prehydrated corticocancellous porcine bone used in maxillary sinus augmentation. Methods: Patients (age 18–70 years) with a residual bone height requiring a maxillary sinus augmentation procedure to place dental implants were eligible for this study. All patients were treated with the same surgical technique consisting of sinus floor augmentation via a lateral approach. The space obtained by elevation of the mucosa wall was grafted with prehydrated and collagenated corticocancellous porcine bone. Biopsies were harvested 6 months after the augmentation procedures. Results: Twenty‐four patients were enrolled. The mean percentage of new formed bone was 43.9 ± 18.6% (range 7.5–100%), whereas the mean percentage of residual graft material was 14.2 ± 13.6% (range 0–41.9%). The new bone/residual graft material ratio in the maxillary sinuses was 3.1. The mean soft tissues percentage was 41.8 ± 22.7% (range 0–92.5%). Conclusion: The present study suggested that porcine bone showed excellent osteoconductive properties and could be used successfully for sinus augmentation. Moreover, the porcine bone showed a high percentage of reabsorption after 6 months; this might be because of the presence of collagen and the porosity of the graft material. 相似文献
178.
179.
MicroRNAs (miRNAs), small non-coding RNAs, play a critical role in differentiation and self-renewal of pluripotent stem cells, as well as in differentiation of cardiovascular lineage cells. Several miRNAs have been demonstrated to repress stemness factors such as Oct4, Nanog, Sox2 and Klf4 in embryonic stem cells, thereby promoting embryonic stem cell differentiation. Furthermore, targeting of different miRNAs promotes reprogramming towards induced pluripotent stem cells. MicroRNAs are critical for vascular smooth muscle cell differentiation and phenotype regulation, and miR-143 and miR-145 play a particularly important role in this respect. Notably, these miRNAs are down-regulated in several cardiovascular disease states, such as in atherosclerotic lesions and vascular neointima formation. MicroRNAs are critical regulators of endothelial cell differentiation and ischaemia-induced neovascularization. miR-126 is important for vascular integrity, endothelial cell proliferation and neovascularization. miR-1 and miR-133 are highly expressed in cardiomyocytes and their precursors and regulate cardiomyogenesis. In addition, miR-499 promotes differentiation of cardiomyocyte progenitor cells. Notably, miRNA expression is altered in cardiovascular disease states, and recent studies suggest that dysregulated miRNAs may limit cardiovascular repair responses. Dysregulation of miRNAs may lead to an altered function and differentiation of cardiovascular progenitor cells, which is also likely to represent a limitation of autologous cell-based treatment approaches in these patients. These findings suggest that targeting of specific miRNAs may represent an interesting novel opportunity to impact on endogenous cardiovascular repair responses, including effects on stem/progenitor cell differentiation and functions. This approach may also serve to optimize cell-based treatment approaches in patients with cardiovascular disease. 相似文献
180.
Zirm E Spies-Weisshart B Heidel F Schnetzke U Böhmer FD Hochhaus A Fischer T Scholl S 《British journal of haematology》2012,157(4):483-492
Fms-like tyrosine kinase (FLT3) mutations are the most frequent mutations in patients with acute myeloid leukaemia (AML) that confer a poor prognosis. Constitutively active FLT3-ITD (internal tandem duplications) mutations define a promising target for therapeutic approaches using small molecule inhibitors. However, several point mutations of the FLT3 tyrosine kinase domain (FLT3-TKD) have been identified to mediate resistance towards FLT3 tyrosine kinase inhibitors (FLT3-TKI), including secondary mutations of FLT3. We investigated the cellular effects of the recently characterised FLT3-TKI ponatinib (AP24534) on murine myeloid cells transfected with FLT3-ITD with or without additional point mutations of the FLT3-TKD including the (so far) multi-resistant F691I mutation. Ponatinib effectively induced apoptosis not only in the parental FLT3-ITD cell line but also in all stably transfected subclones harbouring additional FLT3-TKD point mutations (N676D, F691I or G697R). These observations correlated with a strong inhibition of FLT3-ITD and its downstream targets STAT5, AKT and ERK1/2 upon ponatinib incubation, as determined by Western blotting. We conclude that ponatinib represents a promising FLT3-TKI that should be further investigated in clinical trials. The targeted therapy of FLT3-ITD-positive AML with ponatinib might be associated with a lower frequency of secondary resistance caused by acquired FLT3-TKD mutations. 相似文献